Lynparza approved in Japan for BRCA-mutated metastatic breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AstraZeneca and Merck announced Japan’s Pharmaceuticals and Medical Devices Agency has approved Lynparza (olaparib) tablets for use in patients with unresectable or recurrent BRCA-mutated, human epidermal growth factor receptor 2-negative breast cancer who have received prior chemotherapy. Patients are selected for therapy based on an approved companion diagnostic.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login